Amylyx Pharmaceuticals, Inc.
32.40USD
-1.4800 (-4.37%)
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | $-0.37▼ | $-0.33 | 2 | 4 |
| Next quarter | $-0.37▼ | $-0.34 | 4 | 3 |
| Current year | $-1.5▼ | $-1.38 | 2 | 4 |
| Next year | $-1.15▲ | $-1.27 | 3 | 3 |
Beat in 2 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | $-0.36 | $-0.39 | -0.03 (-9.0%) |
| 2026-03-31 | $-0.34 | $-0.37 | -0.03 (-8.7%) |
| 2025-12-31 | $-0.34 | $-0.3 | +0.04 (+12.2%) |
| 2025-09-30 | $-0.43 | $-0.37 | +0.06 (+13.9%) |
80 ratings from 12 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Guggenheim | Maintained | Buy | $55 $57 | Aug 27, 2026 |
| Mizuho | Maintained | Outperform | $30 $42 | Aug 19, 2026 |
| Guggenheim | Maintained | Buy | $40 $55 | Aug 19, 2026 |
| Baird | Maintained | Outperform | $28 $52 | Aug 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $34 $55 | Aug 18, 2026 |
| Mizuho | Maintained | Outperform | $24 $30 | Aug 17, 2026 |
| Citigroup | Maintained | Buy | $20 $26 | Aug 3, 2026 |
| Mizuho | Maintained | Outperform | $21 $24 | Jul 20, 2026 |
| Guggenheim | Maintained | Buy | $30 $40 | Jun 25, 2026 |
| Mizuho | Maintained | Outperform | $19 $21 | Apr 28, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $34 | Mar 25, 2026 |
| Guggenheim | Maintained | Buy | $25 $30 | Mar 19, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $28 $34 | Mar 4, 2026 |
| Stifel | Initiated | Buy | $21 | Mar 3, 2026 |
| B of A Securities | Maintained | Buy | $15 $19 | Feb 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $20 $28 | Feb 10, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $16 $20 | Nov 7, 2025 |
| Citigroup | Maintained | Buy | $12 $20 | Oct 17, 2025 |
| Baird | Maintained | Outperform | $10 $19 | Oct 16, 2025 |
| B of A Securities | Maintained | Buy | $14 $16 | Oct 3, 2025 |
| Goldman Sachs | Maintained | Buy | $10 $20 | Sep 16, 2025 |
| Guggenheim | Maintained | Buy | $17 $25 | Sep 15, 2025 |
| B of A Securities | Maintained | Buy | $10 $14 | Aug 28, 2025 |
| Guggenheim | Initiated | Buy | $17 | Jun 24, 2025 |
| Citigroup | Initiated | Buy | $12 | Jun 17, 2025 |
76 filings from 9 insiders · 9 buy / 1 sell over 6m
Officers and directors of AMLX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Firestone KarenDirector | ExerciseStock Option (right to buy) | 25.0k | — | — | Aug 31, 2026 |
| Firestone KarenDirector | ExerciseStock Option (right to buy) | 25.0k | — | — | Aug 31, 2026 |
| Firestone KarenDirector | Exercise | 25.0k | $5.05 | $126k | Aug 31, 2026 |
| Firestone KarenDirector | Exercise | 25.0k | $1.76 | $44k | Aug 31, 2026 |
| FRATES JAMES MATTHEWChief Financial Officer | Grant | 22.8k | — | — | Aug 18, 2026 |
| BEDROSIAN CAMILLE LOfficer | Grant | 22.8k | — | — | Aug 18, 2026 |
| MAZZARIELLO GINAOfficer | Grant | 21.3k | — | — | Aug 18, 2026 |
| KLEE JUSTIN BChief Executive Officer | Grant | 60.0k | — | — | Aug 18, 2026 |
| COHEN JOSHUA BARRYChief Executive Officer | Grant | 60.0k | — | — | Aug 18, 2026 |
| MAZZARIELLO GINAOfficer | Sell | 30.0k | $17.61 | $539k | Jul 10, 2026 |
| FIRESTONE KAREN M.Director | Buy | 3.8k | $13.51 | $51k | May 21, 2026 |
| BEDROSIAN CAMILLE LOfficer | Grant | 96.0k | — | — | Mar 5, 2026 |
| FRATES JAMES MATTHEWChief Financial Officer | Grant | 96.0k | — | — | Mar 5, 2026 |
| COHEN JOSHUA BARRYChief Executive Officer | Grant | 248.9k | — | — | Mar 5, 2026 |
| KLEE JUSTIN BChief Executive Officer | Grant | 248.9k | — | — | Mar 5, 2026 |
| MAZZARIELLO GINAOfficer | Grant | 74.7k | — | — | Mar 5, 2026 |
| BEDROSIAN CAMILLE LOfficer | Sell | 6.5k | $14.58 | $94k | Mar 2, 2026 |
| FRATES JAMES MATTHEWChief Financial Officer | Sell | 7.9k | $14.52 | $115k | Mar 2, 2026 |
| COHEN JOSHUA BARRYChief Executive Officer | Sell | 29.3k | $14.48 | $424k | Mar 2, 2026 |
| KLEE JUSTIN BChief Executive Officer | Sell | 29.3k | $14.47 | $424k | Mar 2, 2026 |
No analyst notes on AMLX yet.
Analyst Ratings
11 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 0 | 11 | 1 | 0 | 0 | Buy2.08 |
| 1 mo ago | 0 | 10 | 1 | 0 | 0 | Buy2.09 |
| 2 mo ago | 0 | 11 | 1 | 0 | 0 | Buy2.08 |